This Skadden, Arps, Slate, Meagher & Flom LLP memorandum discusses the dismissal of the Federal Trade Commission's (FTC) antitrust lawsuit alleging that Solvay Pharmaceuticals conspired with generic drug makers Watson Pharmaceuticals and Par Pharmaceuticals to delay generic competition for Androgel, setting back the FTC's campaign against "pay-for-delay" settlements.